108 related articles for article (PubMed ID: 32080141)
1. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
2. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
5. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
6. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
[TBL] [Abstract][Full Text] [Related]
7. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
[TBL] [Abstract][Full Text] [Related]
9. Primum non nocere: Are we ready for POLE testing in endometrial cancer?
Cosgrove CM; Cohn DE; Goodfellow PJ
Gynecol Oncol; 2017 Nov; 147(2):240-242. PubMed ID: 28947175
[No Abstract] [Full Text] [Related]
10. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
[TBL] [Abstract][Full Text] [Related]
11. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
[TBL] [Abstract][Full Text] [Related]
12. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract][Full Text] [Related]
13. Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer.
Zheng S; Donnelly ED; Strauss JB
JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.
Yang Y; Wu SF; Bao W
Int J Gynaecol Obstet; 2024 Feb; 164(2):436-459. PubMed ID: 37525501
[TBL] [Abstract][Full Text] [Related]
16. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
17. Validation of Modaplex POLE mutation assay in endometrial carcinoma.
Dorca E; Velasco A; Varela M; Gatius S; Villatoro S; Fullana N; Cuevas D; Vaquero M; Birnbaum A; Neumann K; Matias-Guiu X
Virchows Arch; 2023 Dec; 483(6):787-794. PubMed ID: 37874375
[TBL] [Abstract][Full Text] [Related]
18. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
[TBL] [Abstract][Full Text] [Related]
19. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.
Huang F; Tanaka H; Knudsen BS; Rutgers JK
BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of circulating tumor cells in esophageal carcinoma: a meta-analysis.
Qiao GL; Qi WX; Jiang WH; Chen Y; Ma LJ
Onco Targets Ther; 2016; 9():1889-97. PubMed ID: 27099520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
